Literature DB >> 22535517

Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.

Pauline S Powers1, Megan Klabunde, Walter Kaye.   

Abstract

OBJECTIVE: Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale-Brown-Cornell Eating Disorder Scale and the Eating Disorder Inventory-2.
METHOD: Participants were randomised to 8 weeks of quetiapine or placebo.
RESULTS: There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression. DISCUSSION: There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups.
Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535517      PMCID: PMC3755505          DOI: 10.1002/erv.2169

Source DB:  PubMed          Journal:  Eur Eat Disord Rev        ISSN: 1072-4133


  12 in total

1.  The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication.

Authors:  James I Hudson; Eva Hiripi; Harrison G Pope; Ronald C Kessler
Journal:  Biol Psychiatry       Date:  2006-07-03       Impact factor: 13.382

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

3.  A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.

Authors:  Vivian Kafantaris; Ellen Leigh; Stanley Hertz; Alison Berest; Janet Schebendach; Wendy Meyer Sterling; Ema Saito; Suzanne Sunday; Claudine Higdon; Neville H Golden; Anil K Malhotra
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-06       Impact factor: 2.576

4.  Mortality in anorexia nervosa.

Authors:  P F Sullivan
Journal:  Am J Psychiatry       Date:  1995-07       Impact factor: 18.112

5.  Ten-year follow-up of adolescent-onset anorexia nervosa: personality disorders.

Authors:  E W Nilsson; C Gillberg; I C Gillberg; M Råstam
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-11       Impact factor: 8.829

6.  Quetiapine in anorexia nervosa patients: an open label outpatient pilot study.

Authors:  Pauline S Powers; Yvonne Bannon; Rebecca Eubanks; Terry McCormick
Journal:  Int J Eat Disord       Date:  2007-01       Impact factor: 4.861

7.  The Yale-Brown-Cornell Eating Disorder Scale: development, use, reliability and validity.

Authors:  C M Mazure; K A Halmi; S R Sunday; S J Romano; A M Einhorn
Journal:  J Psychiatr Res       Date:  1994 Sep-Oct       Impact factor: 4.791

8.  The epidemiology of eating disorders in six European countries: results of the ESEMeD-WMH project.

Authors:  Antonio Preti; Giovanni de Girolamo; Gemma Vilagut; Jordi Alonso; Ron de Graaf; Ronny Bruffaerts; Koen Demyttenaere; Alejandra Pinto-Meza; Josep Maria Haro; Piero Morosini
Journal:  J Psychiatr Res       Date:  2009-05-08       Impact factor: 4.791

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.

Authors:  Hany Bissada; Giorgio A Tasca; Ann Marie Barber; Jacques Bradwejn
Journal:  Am J Psychiatry       Date:  2008-06-16       Impact factor: 18.112

View more
  7 in total

Review 1.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 2.  Pharmacotherapy of eating disorders.

Authors:  Haley Davis; Evelyn Attia
Journal:  Curr Opin Psychiatry       Date:  2017-11       Impact factor: 4.741

Review 3.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 4.  Psychopharmacologic treatment of eating disorders: emerging findings.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Paul E Keck
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

5.  Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients.

Authors:  Mei-Chih Meg Tseng; Chin-Hao Chang; Shih-Cheng Liao; Hsi-Chung Chen
Journal:  BMC Psychiatry       Date:  2017-02-27       Impact factor: 3.630

6.  A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa.

Authors:  Carol Kan; Laura Eid; Janet Treasure; Hubertus Himmerich
Journal:  Front Psychiatry       Date:  2020-03-17       Impact factor: 4.157

Review 7.  Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?

Authors:  Guido K W Frank
Journal:  Expert Opin Pharmacother       Date:  2020-04-13       Impact factor: 3.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.